Impact of baseline hepatitis B virus viral load on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy

Table 3 Subgroup analysis of tumour response according to whether or not they received antiviral therapy, n (%)

	Antiviral therapy (no), n = 25			Antiviral therapy (yes), n = 95
	HBV-DNA (HBV > 2000), n = 8	HBV-DNA (HBV ≤ 2000), n = 18	P value	HBV-DNA (HBV > 2000), n = 46	HBV-DNA (HBV ≤ 2000), n = 48	P value
PR	2 (29)	3 (17)	0.597	15 (32)	10 (21)	0.220
SD	3 (43)	11 (61)	0.656	18 (38)	24 (50)	0.251
PD	2 (29)	4 (22)	> 0.999	14 (30)	14 (29)	0.947
ORR	2 (29)	3 (17)	0.597	16 (34)	10 (21)	0.149
DCR	5 (71)	14 (78)	> 0.999	35 (74)	34 (71)	0.691
ORR (whole)	5 (20)		-	26 (27)		0.454
DCR (whole)	6 (24)		-	26 (27)		0.735

Data in brackets represent the percentages of patients. HBV: Hepatitis B virus; PR: Partial responds; SD: Stable disease; PD: Progression disease; ORR: Objective responds rates; DCR: Disease control rates.